Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
AVTR 
Avantor Inc (AVTR)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/16/2025: AVTR (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
21 Analysts rated it
Well-followed company, solid analyst reports, reliable data for confident investing.
1 Year Target Price $14.06
1 Year Target Price $14.06
| 6 | Strong Buy |
| 4 | Buy |
| 11 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -17.13% | Avg. Invested days 30 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/16/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 8.45B USD | Price to earnings Ratio 12.27 | 1Y Target Price 14.06 |
Price to earnings Ratio 12.27 | 1Y Target Price 14.06 | ||
Volume (30-day avg) 21 | Beta 0.98 | 52 Weeks Range 10.82 - 27.83 | Updated Date 09/15/2025 |
52 Weeks Range 10.82 - 27.83 | Updated Date 09/15/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 1.01 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 10.31% | Operating Margin (TTM) 7.63% |
Management Effectiveness
Return on Assets (TTM) 3.24% | Return on Equity (TTM) 11.73% |
Valuation
Trailing PE 12.27 | Forward PE 12.44 | Enterprise Value 12185303089 | Price to Sales(TTM) 1.27 |
Enterprise Value 12185303089 | Price to Sales(TTM) 1.27 | ||
Enterprise Value to Revenue 1.83 | Enterprise Value to EBITDA 8.64 | Shares Outstanding 681739008 | Shares Floating 663918026 |
Shares Outstanding 681739008 | Shares Floating 663918026 | ||
Percent Insiders 1.37 | Percent Institutions 106.64 |
Upturn AI SWOT
Avantor Inc
Company Overview
History and Background
Avantor, Inc. (formerly Avantor Performance Materials) was founded in 1904. Initially a part of J.T. Baker, it evolved through several acquisitions and divestitures, becoming a standalone company focused on providing products and services to the life sciences and advanced technologies industries. In 2019, Avantor completed its merger with VWR Corporation, significantly expanding its product portfolio and global reach.
Core Business Areas
- Materials and Consumables: Offers a range of high-purity chemicals, lab products, consumables, and customized solutions used in research, development, and production processes across various industries.
- Equipment and Instrumentation: Provides a broad portfolio of equipment, instruments, and related services to research and clinical laboratories.
- Services and Solutions: Offers a range of services, including procurement, lab support, single-use solutions, and bioprocessing solutions.
Leadership and Structure
Avantor is led by President and CEO Michael Stubblefield. The organizational structure includes various business units and functional departments, reporting to the executive leadership team, which is accountable to the board of directors.
Top Products and Market Share
Key Offerings
- High-Purity Chemicals: A wide range of high-purity chemicals used in various applications, including pharmaceuticals, electronics, and research. Avantor is a significant player in this market, competing with companies like Merck KGaA and Thermo Fisher Scientific. Revenue data isn't publicly broken down by product, but it is a core offering.
- competitors: Merck KGaA,Thermo Fisher Scientific
- Lab Products and Consumables: A broad portfolio of lab products and consumables, including filters, pipette tips, and cell culture media. The overall market share for lab products and consumables is fragmented, with Avantor competing with several major players like Thermo Fisher Scientific, Corning, and Sartorius.
- competitors: Thermo Fisher Scientific,Corning,Sartorius
- Single-Use Solutions: Provides single-use bioprocessing solutions. The market is growing at a CAGR of 15%. Avantor holds a significant market share in this space, competing with Danaher and Sartorius. Revenue data isn't publicly broken down by product, but it is a core offering.
- competitors: Danaher,Sartorius
Market Dynamics
Industry Overview
The life sciences and advanced technologies industries are experiencing growth, driven by factors such as increasing research and development spending, advancements in biopharmaceuticals, and growth in the electronics and semiconductor industries. Regulatory requirements and the need for high-quality products are key industry drivers.
Positioning
Avantor is positioned as a leading provider of high-purity materials, consumables, equipment, and services to the life sciences and advanced technologies industries. Its competitive advantages include its broad product portfolio, global reach, strong customer relationships, and focus on innovation.
Total Addressable Market (TAM)
The Total Addressable Market (TAM) for Avantor's products and services is estimated to be over $80 billion. Avantor is well-positioned to capture a significant share of this market, given its comprehensive product portfolio, global presence, and strong customer relationships.
Upturn SWOT Analysis
Strengths
- Broad product portfolio
- Global reach and distribution network
- Strong customer relationships
- Focus on innovation and new product development
- Expertise in high-purity materials and consumables
Weaknesses
- Integration risks associated with acquisitions
- Dependence on key suppliers
- Exposure to economic cycles
- Potential for product recalls
Opportunities
- Expanding into new geographic markets
- Developing new products and services for emerging technologies
- Acquiring complementary businesses
- Increasing demand for biopharmaceuticals and advanced technologies
- Growing outsourcing trend in R&D
Threats
- Increased competition
- Economic downturn
- Changes in regulatory requirements
- Disruptive technologies
- Supply chain disruptions
Competitors and Market Share
Key Competitors
- Thermo Fisher Scientific (TMO)
- Danaher Corporation (DHR)
- Merck KGaA (MRK.DE)
- Sartorius AG (SRT.DE)
Competitive Landscape
Avantor benefits from a broad product portfolio and a strong global presence. Its main disadvantage is the leverage taken on for acquisitions. Competitors like Thermo Fisher Scientific have a larger market capitalization and diverse revenue streams.
Major Acquisitions
Masterflex Bioprocessing
- Year: 2021
- Acquisition Price (USD millions): 296
- Strategic Rationale: Expanded Avantor's single-use bioprocessing capabilities and product offerings, enhancing its position in the biopharmaceutical market.
Growth Trajectory and Initiatives
Historical Growth: Avantor has experienced strong historical growth, driven by organic growth and strategic acquisitions.
Future Projections: Analysts project continued revenue growth for Avantor, driven by increasing demand for its products and services. Profitability is also expected to improve due to cost optimization initiatives.
Recent Initiatives: Recent strategic initiatives include expanding into new geographic markets, developing new products and services, and acquiring complementary businesses. Investment into single-use technologies.
Summary
Avantor is a leading provider in the life sciences and advanced technologies industries with a broad product portfolio and global reach. Its strategic acquisitions have fueled growth, but have also increased its debt. The company's focus on innovation and customer relationships positions it well for future growth, but it faces threats from increased competition and economic cycles. Despite some weaknesses, Avantor is a strong player in its industry.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Filings (10-K, 10-Q)
- Investor Presentations
- Analyst Reports
- Market Research Reports
- Company Website
Disclaimers:
The information provided is for informational purposes only and should not be construed as investment advice. Market share estimates are approximate and based on available data. Financial data is based on publicly available information and may be subject to change. The AI-based rating is based on an algorithm and should not be the sole basis for investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Avantor Inc
Exchange NYSE | Headquaters Radnor, PA, United States | ||
IPO Launch date 2019-05-17 | President & CEO Mr. Emmanuel Ligner | ||
Sector Healthcare | Industry Medical Instruments & Supplies | Full time employees 13500 | Website https://www.avantorsciences.com |
Full time employees 13500 | Website https://www.avantorsciences.com | ||
Avantor, Inc. engages in the provision of mission-critical products and services to customers in the biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa. The company offers materials and consumables, such as purity chemicals and reagents, lab products and supplies, formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits, education and microbiology products, clinical trial kits, and fluid handling tips. It also provides equipment and instrumentation products, including filtration systems, virus inactivation systems, incubators, analytical instruments, evaporators, ultra-low-temperature freezers, biological safety cabinets, peristaltic pumps, and critical environment supplies. In addition, the company offers services and specialty procurements comprising onsite lab and production, equipment, procurement and sourcing, and biopharmaceutical material scale-up and development services. Further, it provides scientific research support services, such as DNA extraction, bioreactor servicing, clinical and biorepository, compound management, cleanroom control, monitoring, maintenance, and sanitization services. The company was founded in 1904 and is headquartered in Radnor, Pennsylvania.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.